Y-mAbs to Participate at Upcoming Investor Conferences in September
06 Septiembre 2023 - 3:05PM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB), a commercial-stage biopharmaceutical company focused on the
development and commercialization of novel, antibody-based
therapeutic products for the treatment of cancer, today announced
that the Company will participate at the following upcoming
investor conferences:
- Thomas Gad, Founder, President and Interim Chief Executive
Officer, will participate in a fireside chat at the H.C.
Wainwright 25th Annual Global
Investment Conference in New York, NY on Monday, September
11, 2023 at 11:30 a.m. ET.
- Mr. Gad and and Bo Kruse, Chief Financial Officer, will
participate in one-on-one meetings at the Morgan Stanley
21st Annual Global Healthcare
Conference in New York, NY on Tuesday, September 12,
2023.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical
company focused on the development and commercialization of novel,
antibody-based therapeutic cancer products. In addition to
conventional antibodies, the Company’s technologies include
bispecific antibodies generated using the Y-BiClone platform and
the SADA platform. The Company’s broad and advanced product
pipeline includes one FDA-approved product, DANYELZA®
(naxitamab-gqgk), which targets tumors that express GD2, and one
product candidate, OMBLASTYS® (omburtamab), which targets tumors
that express B7-H3.
Forward-Looking
StatementsStatements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited
to, statements about our business model, including the Company’s
plans and strategies, development, commercialization and product
distribution plans; expectations with respect to our products and
product candidates, including the potential of DANYELZA and product
candidates based on the SADA technology and the potential benefits
thereof; and other statements that are not historical facts.. Words
such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’
‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’
‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’
‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance,” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Our product candidates and related technologies
are novel approaches to cancer treatment that present significant
challenges. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
factors, including but not limited to: risks associated with our
financial condition and need for additional capital; the risks that
actual results of our restructuring plan and revised business plan
will not be as expected; risks associated with our development
work; cost and success of our product development activities and
clinical trials; the risks of delay in the timing of our regulatory
submissions or failure to receive approval of our drug candidates;
the risks related to commercializing any approved pharmaceutical
product including the rate and degree of market acceptance of our
product candidates; development of our sales and marketing
capabilities and risks associated with failure to obtain sufficient
reimbursement for our products; the risks related to our dependence
on third parties including for conduct of clinical testing and
product manufacture; our inability to enter into partnerships; the
risks related to government regulation; risks related to market
approval, risks associated with protection of our intellectual
property rights; risks related to employee matters and managing
growth; risks related to our common stock, risks associated with
macroeconomic conditions, including the conflict between Russia and
Ukraine and sanctions related thereto, inflation, increased
interest rates, uncertain global credit and capital markets and
disruptions in banking systems; and other risks and uncertainties
affecting the Company including those described in the "Risk
Factors" section included in the Company’s Annual Report on Form
10-K for the fiscal year ending December 31, 2022, the Company’s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2023,
the Company’s Quarterly Report on Form 10-Q for the quarter ended
June 30, 2023 and future filings and reports by the Company. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and the Company undertakes no
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
DANYELZA®, OMBLASTYS® and Y-mAbs® are registered
trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney DuganVP, Head of Investor Relationscdu@ymabs.com
Y mAbs Therapeutics (NASDAQ:YMAB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024